Evogene Ltd. Q2 2025 Earnings Recap

Evogene reported significant revenue growth and reduced operating expenses amid a strategic transition focused on its ChemPass AI platform. The company anticipates realizing full benefits from cost-cutting measures in the latter half of 2025.

Key Takeaways

• Total revenues rose to approximately $3.2 million for H1 2025, up from $2.3 million in H1 2024, driven by strong seed sales from Casterra.
• Research and development expenses decreased to $4.8 million due to reduced activities at Biomica and the discontinuation of Canonic.
• Total operating expenses fell significantly to $7.7 million, down from $11.1 million, primarily due to streamlined operations and a lower headcount.
• Evogene began a strategic shift towards enhancing its ChemPass AI platform, resulting in the successful completion of a generative AI model for small molecule design in collaboration with Google Cloud.